Lisata Therapeutics (LSTA) and WARPNINE Incorporated announced the successful completion of patient enrollment in the Phase 1b/2a iLSTA trial in Australia. The study is evaluating certepetide, Lisata’s proprietary iRGD cyclic peptide product candidate, in combination with standard-of-care chemotherapy and immunotherapy as a first-line treatment in locally advanced non-resectable pancreatic ductal adenocarcinoma and was conducted wholly at St John of God Subiaco Hospital, a tertiary private hospital with one of the busiest clinical trial units in the Southern Hemisphere.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LSTA:
- Lisata Therapeutics price target raised to $32 from $20 at Brookline
- Lisata Therapeutics Secures U.S. Patent for Certepetide
- Lisata Therapeutics Reveals Promising Phase 2 Trial Data
- Lisata Therapeutics announces preliminary cohort B results from ASCEND trial
- Strategic Collaboration with GATC Health Boosts Lisata Therapeutics’ Growth Potential